

Wenzhen Duan, M.D., Ph.D.

Director of Laboratory of Translational Neurobiology,
Department of Psychiatry & Behavioral Sciences,
Johns Hopkins University School of Medicine.
CMSC 8-121, 600 North Wolfe Street,
Baltimore, MD 21287.
410-502-2866 (P); 410- 614-0013(F); wduan2@jhmi.edu



DEMOGRAPHIC INFORMATION**Current Appointments**

- 2010-Present Associate Professor, Division of Neurobiology, Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine
- 2012-Present Associate Professor, Department of Neuroscience, Johns Hopkins University School of Medicine
- 2012-Present Faculty, Neuroscience Graduate Program, Johns Hopkins University School of Medicine
- 2008-Present Faculty, Cellular and Molecular Medicine Graduate Program, Johns Hopkins University School of Medicine
- 2006-Present Director, Laboratory of Translational Neurobiology, Division of Neurobiology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
- 2006-present Faculty, Baltimore Huntington's Disease Center

Education and Training

- 1987-1992 M.D., Shanxi Medical University, Taiyuan, Shanxi, China
- 1992-1995 M.S., Pharmacology, Shanxi Medical University, Shanxi, China
- 1995-1998 Ph.D., Neuropharmacology, Peking Union Medical College, Beijing, China
- 1998-2000 Postdoctoral Fellow, Neurobiology, University of Kentucky, Lexington, KY

Professional Experience

- 2000-2004 Senior Research Scientist, Lab of Neuroscience, National Institute on Aging, NIH, Baltimore, MD
- 2004-2006 Instructor, Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 2006-2010 Assistant Professor, Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 2010-Present Associate Professor, Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

RESEARCH ACTIVITIES**Peer-Reviewed Original Research Publications (In reversed chronological order)**

1. Jiang M, Zheng J, Peng Q, Hou Z, Zhang J, Mori S, Ellis JL, Vlasuk GP, Fries H, Suri V, **Duan W**. Sirtuin 1 activator SRT2104 protects Huntington's disease mice. **Annals of Clinical and Translational Neurology** 2014, *In press*.
2. Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, Mori S, Ross CA, Ye K and **Duan W**. Small molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. **Hum Mol Genet** 2013, 22(12):2462-2470.
3. Jin J, Albertz J, Guo Z, Peng Q, Rudow G, Troncoso JC, Ross CA, **Duan W**. Neuroprotective effects of PPAR- γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. **J Neurochem**, 2013,125(3):410-419.
4. Jin J, Cheng Y, Zhang Y, Wood W, Peng Q, Hutchison E, Mattson MP, Becker KG, **Duan W**. Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin. **J Neurochem**, 2012, 123(4): 477-90.
5. Fu J, Jin J, Cichewicz RH, Hageman SA, Ellis TK, Xiang L, Peng Q, Jiang M, Arbez N, Hotaling K, Ross CA and **Duan W**. *Trans(-)- ϵ -viniferin* increases mitochondrial sirtuin 3 (SIRT3), activates AMPK, and protects cells in models of Huntington's disease. **J. Bio Chem**, 2012, 287(29):24460-72.
6. Guo Z, Rudow G, Pletnikova O, Codispoti KE, Orr BA, Crain BJ, **Duan W**, Margolis RL, Rosenblatt A, Ross CA, Troncoso JC. Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. **Mov Disord**. 2012, 27(11):1379-86.
7. Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, Arbez N, Graham R, Hayden M, Hou Z, Mori S, Swing D, Pletnikov M, **Duan W**, Tessarollo L, Ross CA. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. **J Neurosci** 2012, 32(1):183-193.
8. Aggarwal M, **Duan W**, Hou Z, Rakesh N, Peng Q, Ross CA, Miller MI, Mori S, Zhang J. Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo Magnetic resonance imaging. **Neuroimage** 2012, 60(4):2086-95
9. Jiang M, Wang J, Fu J, Du L, Jeong H, West T, Xiang L, Peng Q, Hou Z, Cai H, Seredenin T, Arbez N, Zhu S, Sommers K, Qian J, Zhang J, Mori S, Yang XW, Tamashiro KLK, Aja S, Moran TH, Luthi-Carter R, Martin B, Maudsley S, Mattson MP, Cichewicz RH, Ross CA, Holtzman DM, Krainc D, **Duan W**. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. **Nature Medicine**, 2011, 18(1): 153-158.
10. Cheng Y, Peng Q, Hou Z, Aggarwal M, Zhang J, Mori S, Ross CA, **Duan W**. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. **Neuroimage**, 2011, 56:1027-1034.
11. Xiang Z, Valenza M, Cui L, Leoni V, Jeong H, Brilli E, Zhang J, Peng Q, **Duan W**, Reeves S, Cattaneo E, Krainc D. PGC-1 α contributes to dysmyelination in experimental models of Huntington's disease. **J Neuroscience** 2011,31(26):9544-53.
12. Jiang M, Porat-Shliom Y, Pei Z, Cheng Y, Xiang L, Sommers K, Li Q, Gillardon F, Hengerer B, Berlinicke C, Smith WW, Zack D, Poirier MA, Ross CA, **Duan W**. Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familial Parkinsonism. **J Neurochem**, 2010, 114(2):419-29.
13. Zhang J, Peng Q, Li Q, Jahanshad N, Hou Z, Jiang M, Masuda N, Langbehn DR, Miller MI, Mori S, Ross CA, **Duan W**. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. **Neuroimage**, 2010, 49(3):2340-51.
14. Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, **Duan W**. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. **Neurobio Dis**, 2008; 30:293-302.

15. **Duan W**, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, Zhao M, Cadet JL, Wong J, Ross CA. Sertraline Slows Disease Progression and Increases Neurogenesis in N171-82Q mouse model of Huntington's Disease. *Neurobio Dis*, 2008, 30: 312-322.
16. Peng Q, Naoki M, Jiang M, Li Q, Zhao M, Ross CA, **Duan W**. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. *Exp Neurol*. 2008, 210:154-163.
17. Kostka M, Högen T, Danzer KM, Levin J, Habeck M, Wirth A, Wagner R, Glabe CG, Finger S, Heinzelmann U, Garidel P, **Duan W**, Ross CA, Kretschmar H, Giese A. Single-particle characterization of iron-induced pore-forming alpha -synuclein oligomers. *J Biol Chem*. 2008, 283(16):10992-11003
18. Guo Z, Jiang H, Xu X, **Duan W**, Mattson MP. Leptin-mediated cell survival signaling in hippocampal neurons mediated by Jak /Stat3 and mitochondrial stabilization. *J Bio Chem*. 2008, 283(3):1754-63.
19. Williams RB, Gutekunst WR, Joyner PM, **Duan W**, Li Q, Ross CA, Williams TD, Cichewicz RH. Bioactivity Profiling with Parallel Mass Spectrometry Reveals an Assemblage of Green Tea Metabolites Affording Protection against Human Huntingtin and alpha-Synuclein Toxicity. *J Agric Food Chem*. 2007, 55(23):9450-6.
20. Xu X, Zhan M, **Duan W**, Prabhu V, Brennehan R, Wood W, Firman J, Li H, Zhang P, Ibe C, Zonderman AB, Longo DL, Poosala S, Becker KG, Mattson MP. Gene expression atlas of the mouse central nervous system: impact and interactions of age, energy intake and gender. *Genome Biol*. 2007, 8(11):R234.
21. Sredni B, Geffen-Aricha R, **Duan W**, Albeck M, Shalit F, Lander HM, Kinor N, Sagi O, Albeck A, Yosef S, Brodsky M, Sredni-Kenigsbuch D, Sonino T, Longo DL, Mattson Ddagger 1 MP, Yadid G. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. *FASEB J*.2007, 21(8):1870-83.
22. Wang W, **Duan W**, Igarashi S, Morita H, Nakamura M, Ross CA. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. *Neurobio Dis* 2005, 20(2):500-8.
23. **Duan W**, Guo Z, Jiang H, Ladenheim B, Xu X, Cadet JL, Mattson MP. Paroxetine retards disease onset and progression in Huntington mutant mice. *Ann Neurol* 2004, 55(4):590-4.
24. **Duan W**, Guo ZH, Jiang H, Ware M, Mattson MP. Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. *Endocrinology* 2003,144(6):2446-53.
25. **Duan W**, Guo ZH, Jiang HY, Ware M, Li XJ, Mattson MP. Dietary Restriction Normalizes Glucose Metabolism and BDNF Levels, Slows Disease Progression and Increases Survival in Huntington Mutant Mice. *Proc. Natl. Acad. Sci. U S A* 2003,100(5):2911-6.
26. **Duan W**, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. *J Neurochem*. 2002, 80(1):101-10.
27. Lee J, **Duan W**, Mattson MP. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. *J Neurochem* 2002,82(6):1367-75
28. **Duan W**, Zhu X, Ladenheim B, Yu QS, Guo ZH, Olyer J,Cutler RG, Cadet JL, Greig NH and Mattson MP . Synthetic p53 Inhibitors Preserve Dopaminergic Neurons and Motor Function in Experimental Parkinsonism. *Ann Neurol* 2002,52:597-606.
29. Lee J, **Duan W**, Long JM, Ingram DK and Mattson MP. Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. *J Mol Neurosci* 2001, 15: 99-108.

30. **Duan W**, Lee J, Guo Z, Mattson MP. Dietary restriction stimulates BDNF production in the brain and thereby protects neurons against excitotoxic injury. *J Mol Neurosci*. 2001,16(1):1-12.
31. **Duan W**, Guo ZH, Mattson MP. Brain-derived neurotrophic factor mediates an excitoprotective effect of dietary restriction in mice. *J Neurochem*, 2001, 76:619-626.
32. **Duan W**, Guo ZH, Mattson MP. Participation of Par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-NP. *Exp. Neurology*, 2000, 165:1-11
33. **Duan W** and Mattson MP. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. *J Neurosci Res*, 1999,57:195-206.
34. **Duan W**, Rangnekar VM and Mattson MP. Prostate Apoptosis Response-4 production in synaptic compartments following apoptotic and excitotoxic insults: Evidence for a pivotal role in mitochondrial dysfunction and neuronal degeneration. *J Neurochem*, 1999,72:2312-2322.
35. Begley JG, **Duan W**, Chan SL, Mattson MP. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. *J Neurochem* 1999,72(3):1030-9.
36. **Duan W**, Zhang Z, Gash DM, Mattson MP. Participation of Prostate Apoptosis Response-4 in Degeneration of Dopaminergic Neurons in Models of Parkinson's Disease. *Ann Neurol* 1999, 46:587-597.
37. **Duan W**, Zhang JT. Inhibitory effects of (-),(+)clausenamide on cholinesterase in vitro. *Chinese J Pharmacology & Toxicology* 1998,12(1):16-19.
38. **Duan W**, Zhang JT. Stimulation of central cholinergic neurons by (-) clausenamide. *Acta Pharmacologica Sinica* 1998,19(4):332-336.
39. **Duan W**, Zhang JT. Effects of clausenamide on anisodine-induced acetylcholine decrease and memory deficits in the mouse brain. *Chinese Medical Journal* 1998,111(11): 1035-1038.
40. Zhang JT, **Duan W**, Wu J. Gene regulation of apoptosis and study of anti-neuronal apoptotic agents. *Acta Pharmaceutica Sinica*, 1998, 33(1):75-79.
41. **Duan W**, Zhang JT. Learning & Memory, LTP and message molecule. *Chinese Pharmacological Bulletin* 1998,14(5):120-125.
42. **Duan W**, Liang Y, Tang YZ. Protection of zinc sulfate on acute cerebral ischemia reperfusion injury in rats. *Chinese Pharmacological Bulletin* 1997,13(1):39-42.
43. **Duan W**, Zhang JT. Effects of (-),(+)clausenamide on NMDA receptors in rodent. *Acta Pharmaceutica Sinica* 1997, 32(4):259-263
44. **Duan W**, Zhang JT. Determination of acetylcholine and choline content of mouse brain by HPLC-ER-ECD. *Acta Pharmaceutica Sinica* 1997, 32(12):920-923.
45. **Duan W**, Tang YZ. Effects of methylflavonolamine on free intracellular calcium in isolated embryonic rat brain cells. *Acta Pharmacologica Sinica* 1996,17(4): 305-309.
46. **Duan W**, Tang YZ et al. Effects of potassium quercetin phosphate on acute cerebral ischemia reperfusion injury and relationship to calcium. *Chinese Pharmaceutical J* 1996, 31(9):554.
47. **Duan W**, Tang YZ et al. Effects of methylflavonolamine on acute forebrain ischemia reperfusion injury in rats. *Chinese J Pharmacology & Toxicology* 1996,10(2):89-93.

Peer Reviewed Review Articles

1. **Duan W**, Jiang M, Jin J. Metabolism in HD- Still a relevant mechanism? *Mov Dis* 2014, 29(11):1366-1374.
2. **Duan W**. Sirtuins: from metabolic regulation to brain aging. *Frontiers in Aging Neuroscience* 2013, 5(36): 1-13.

3. **Duan W.** Targeting sirtuin-1 in Huntington's disease: rationale and current status. *CNS Drugs* 2013, 27(5):345-352.
4. **Duan W, Ross CA.** Potential therapeutic targets for neurodegenerative diseases: lessons learned from calorie restriction. *Current Drug Target* 2010, 11(10):1281-92.
5. Mattson MP, **Duan W, Wan R, Guo Z.** Prophylactic Activation of Neuroprotective Stress Response Pathways by Dietary and Behavioral Manipulations. *NeuroRx*. 2004;1(1):111-116.
6. Mattson MP, **Duan W, Guo Z.** Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. *J Neurochem*. 2003, 84(3):417-431.
7. Mattson MP, **Duan W, Wan R, Guo Z.** Cellular and molecular mechanisms whereby dietary restriction extends healthspan: a beneficial type of stress. *Advances in Cell Aging and Gerontology* 2003,14: 87-103.
8. Mattson MP, Chan SL, **Duan W.** Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. *Physiol Rev*. 2002, 82(3):637-72.
9. Mattson MP, **Duan W, Maswood N.** How does the brain control lifespan? *Ageing Res Rev*. 2002, 1(2):155-65.
10. Mattson MP, Kruman II, **Duan W.** Folic acid and homocysteine in age-related disease. *Ageing Res Rev*. 2002, 1(1):95-111.
11. Mattson MP, **Duan W, Chan SL, Cheng A, Haughey N, Gary DS, Guo Z, Lee J, Furukawa K.** Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior. *Neurobiol Aging*. 2002 p, 23(5):695.
12. Mattson MP, **Duan W, Chan SL, Cheng A, Haughey N, Gary DS, Guo Z, Lee J, Furukawa K.** Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior. *Neurobiol Aging*. 2002 p, 23(5):695.
13. Mattson MP, Gary DS, Chan SL, **Duan W.** Perturbed endoplasmic reticulum function, synaptic apoptosis and the pathogenesis of Alzheimer's disease. *Biochem Soc Symp*. 2001, (67):151-62.
14. Mattson MP, **Duan W, Lee J, Guo ZH.** Suppression of brain aging and neurodegenerative disorders by dietary restriction and environmental enrichment molecular mechanism. *Mechanisms of Ageing and Development* 2001, 122:757-778.
15. Mattson MP, **Duan W, Pedersen WA, Culmsee C.** Neurodegenerative disorders and ischemia brain disease. *Apoptosis* 2001, 6(1-2):69-81.
16. Mattson MP, **Duan W, Lee J, Guo Z, Roth GS, Ingram DK, Lane MA.** Progress in the development of calorie restriction mimetic dietary supplements. *J Anti-Aging Med*. 2001, 4(3): 225-232.
17. Mattson MP, **Duan W, Chan SL, Camandola S.** Par-4: an emerging pivotal player in neuronal apoptosis and neurodegenerative disorders. *J Mol Neurosci*. 1999,13(1-2):17-30.
18. Mattson MP, **Duan W.** "Apoptotic" biochemical cascades in synaptic compartments: roles in adaptive plasticity and neurodegenerative disorders. *J Neurosci Res*. 1999,58(1):152-66.
19. Mattson MP, Pedersen WA, **Duan W, Culmsee C, Camandola S.** Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. *Ann N Y Acad Sci*. 1999, 893:154-75.

EDUCATIONAL ACTIVITIES

Educational publications

Book Chapter

Mattson MP, **Duan W, Chan SL, Guo ZH.** Apoptotic and antiapoptotic signaling at the synapses: from adaptive plasticity to neurodegenerative disorders. Toward a theory of Neuroplasticity. *Psychology press* 2001, p402.

Teaching***Classroom instruction***

2008-present Cellular and Molecular Medicine Graduate Program Topics class
 2012-present Neuroscience Graduate Program Topic class

Mentoring**Advisees***Faculty:*

Mali Jiang, Ph.D. 2013-Present, Research Associate. Johns Hopkins University

Postdoc Fellows:

Naoki Masuda, M.D. 2004-2009, Postdoc Fellow, Currently Attending Neurologist in Tokyo University, Japan.
 Mali Jiang, Ph.D. 2007-2013, Post-doctoral Fellow, current faculty in Johns Hopkins University.
 Yong Cheng, Ph.D. 2008-2010, Post-doctoral Fellow, Currently General Manager of National Institute of Pharmaceutical R&D Co. Ltd, China.
 Lan Xiang, Ph.D. 2008-2009, Post-doctoral Fellow, Currently Professor of Pharmacology, Shandong University, China.
 Jiawei, Wang, M.D. 2008-2010, Postdoctoral Fellow, Currently Professor of Department of Neurology, Beijing Friendship Hospital, China.
 Jinrong Fu, Ph.D. 2009-2011, Postdoctoral Fellow.
 Jing Jin, Ph.D. 2009-Present, Postdoctoral Fellow
 Nicolas Arbez, Ph.D. 2009-2010, Postdoctoral Fellow.
 Gengze Wei, Ph.D. 2012.2-12, Postdoctoral Fellow, Currently a Postdoc Associate in Washington State University
 Tianhua Ren, M.D. 2014-Current, Postdoc Fellow
 Bin Wu, M.D., Ph.D. 2014-Current, Postdoc Fellow

Staffs:

Qi Peng, B.A. 2004-Present, Research Specialist
 Qing Li, Ph.D. 2006-2008, Research Specialist.

Predoctoral trainees:

Jennifer Albertz 2011, Graduate student of Cellular Molecular Medicine
 Catherine Sommers 2008-2010, Currently M.D., Ph.D candidate of Northwestern University School of Medicine
 Jennifer Qian 2011, Undergraduate of McGill University
 Katelyn Hotaling 2011, Undergraduate of Johns Hopkins University School of Public health
 Michael Tao 2012- 2014, Johns Hopkins Undergraduate student
 Jennifer Zheng 2012- Present, Johns Hopkins Undergraduate student
 Sonya Abadali 2013-2014, Johns Hopkins Undergraduate student
 Rafael Ornelas 06/2014-08/2014, University of California Riverside School of Medicine
 Merit Scholarship awarded student summer research internship

Training grant participation

- 7/2008-present Interdisciplinary Training in Psychiatry & Neuroscience
T32MH015330-30
NIH/NIMH
PI: Christopher A. Ross
Role: Program faculty
- 12/2008-present Training Program in Cellular and Molecular Medicine (CMM)
T32GM008752-09
NIH/NIGMS
PI: Rajini Rao
Role: Program faculty

ORGANIZATIONAL ACTIVITIES**Institutional Administrative Appointments**

- 2008-present Member, Search committee for the Cellular and Molecular Medicine (CMM) Graduate Program.
- 2012-Present Member, Search committee for the Neuroscience Graduate Program.

Editorial Activities

- 2010- Present Editorial Board member of IRSN Neurology
- 2012- Present Editorial Board member of Neurobiology of Aging
- 2012- Present Editorial Board member of Neuromolecular Medicine
- 2013- Present Editorial Board member of Advances in Medicine
- 2013- Present Editorial Board member of World Journal of Biological Chemistry

Regular Journal Reviewer

- 2003-Present Neurobiology of Aging
- 2003-Present J Neuroscience Research
- 2003-Present Neuromolecular Medicine
- 2003-Present Brain Research
- 2007-Present Neuroscience
- 2007-Present Journal of Neurochemistry
- 2008-Present J Neuroendocrinology
- 2008-Present Human Molecular Genetics
- 2008-Present Journal of Cell Biology
- 2008-present Journal of Biological Chemistry
- 2008-Present Journal of Neuroscience

Professional Membership

- 1998-Present Regular Member of Society for Neuroscience (SFN)
- 1998-Present Regular Member of American Society of Neurochemistry (ASN)
- 2008-Present Member of American Society for Experimental Neurotherapeutics (ASENT).
- 2013-Present Member of Academic Drug Discovery Consortium (ADDC).
- 2014-Present Member of International Society of Neurochemistry (ISN)

Ad-hoc grant reviewer

- 2007 The Wellcome Trust grant

- 2010 European Parkinson's Disease Association grant
- 2013 Austrian Science Fund grant
- 2014 UK Medical Research Council (MRC) grant

NIH study section review member

- 2013 Review panel member of NIDA ZDA1 GXM-A 12R on Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R01) (R21).
- 2014 Review panel member of NIGMS ZGM1 TWD-6 (SC) on Support of Competitive Research (SCORE) applications.
- 2014 Review panel member of MDCN-Q(05) M Special emphasis panel on Mechanisms of Neurodegenerative Disease and Injury applications

Conference Organizer, Session Chair

- 08/2004 Session Chair, American Society of Neurochemistry 35th Annual meeting. New York, NY, USA
- 11/2010 Symposium Chair, 40th Society of Neuroscience conference, Huntington's disease: Animal Model I. San Diego, CA, USA
- 07/2013 Session Chair, Neuropsychopharmacology section. 12th Meeting of the Asia-Pacific Federation of Pharmacologists, Shanghai, China
- 03/2015 Symposium organizer and Chair, Revisit mitochondria in neurodegeneration. 46th American Society for Neurochemistry Annual meeting. Atlanta, GA, USA

RECOGNITION

Awards and Honors

- 1999 Glenn Award, American Aging Association.
- 1999 Postdoc travel award, American Society of Neurochemistry
- 2000 The New Milton Wexler Postdoctoral Research Fellowship, Hereditary Disease Foundation (HDF).
- 2002 NIH intramural Research Fellowship
- 2005 Young Investigator Travel Award, Gordon Conference (CAG Repeat)
- 2011 Woman's Leadership Program, Johns Hopkins University

Invited Talks/Panels

- 1999 28th American Aging Association Annual meeting. Seattle, WA.
- 2001 30th American Aging Association Annual meeting. Madison, WI.
- 2004 Neuroscience Program at USUHS. Bethesda, MD.
- 2004 Society for Neuroscience (SFN) Annual meeting symposium. San Diego, CA
- 2005 Johns Hopkins Psychiatry Research Conference. Baltimore, MD.
- 2008 Emory Center for Neurodegenerative Disease. Atlanta, GA.
- 2008 Johns Hopkins University School of Medicine, Psychiatry Research potpourri. Baltimore, MD.
- 2008 Johns Hopkins University Center for Imaging Science. Baltimore, MD.
- 2008 Professional workshop on discussion of MRI assessment in mouse models of Huntington's disease, sponsored by CHDI foundation, New York, NY.
- 2009 11th Annual ASENT meeting. Arlington, VA.
- 2009 Gordon Research Conference- CAG Triplet Repeat Disorders. Waterville Valley, NH.
- 2009 PENS (Program of European Neuroscience School). "Metabolic Aspect of Chronic Brain Diseases," Günzburg, Germany.
- 2009 University of Iowa Neurology Grand Round. Iowa city, Iowa.
- 2010 5th CHDI Therapeutics Conference, Palm Spring, California.

- 2010 Neuron to Synapse 2010 meeting, New York, NY.
- 2010 Drug Development Conference. Beijing, China
- 2010 Hereditary disease foundation (HDF) conference 2010. Boston, MA.
- 2010 Professional workshop on Neurodevelopmental Neurobiology of Huntington's disease, sponsored by CHDI foundation, New York, NY.
- 2010 Society of Neuroscience 2010 conference Nanosymposium. San Diego, CA
- 2011 6th CHDI Therapeutic Conference. Palm Springs, CA.
- 2011 Temple University, Department of Neuroscience,. Philadelphia, PA.
- 2012 KEYSTONE Symposia on Sirtuins in Metabolism, Aging and Disease. Tahoe city, CA
- 2012 University of Miami, Department of Psychiatry and Behavioral Sciences Research Seminar, Miami, FL.
- 2012 Society for Neuroscience 2012 Mini-symposium “ Systemic pathology in neurodegeneration: The case of Huntington's disease”. New Orleans, LA.
- 2013 Invited speaker, Chinese Institute of *Materia Medica*, Chinese Institute of Medical Sciences, “Therapeutic development for neurological diseases: Current challenges and opportunities”, July 8, 2013, Beijing, China.
- 2013 12th Meeting of the Asia-Pacific Federation of Pharmacologists, Invited symposium speaker. “ Targeting Sirtuin-1 in Huntington's disease: Rationale and Current status”. July 9-13, 2013, Shanghai, China.